864 related articles for article (PubMed ID: 20119833)
1. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
[TBL] [Abstract][Full Text] [Related]
2. CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
Waldeck S; Rassner M; Keye P; Follo M; Herchenbach D; Endres C; Charlet A; Andrieux G; Salzer U; Boerries M; Duyster J; von Bubnoff N
Mol Oncol; 2020 Apr; 14(4):779-794. PubMed ID: 31955503
[TBL] [Abstract][Full Text] [Related]
3. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
Seedhouse CH; Hunter HM; Lloyd-Lewis B; Massip AM; Pallis M; Carter GI; Grundy M; Shang S; Russell NH
Leukemia; 2006 Dec; 20(12):2130-6. PubMed ID: 17066094
[TBL] [Abstract][Full Text] [Related]
4. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
Park IK; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA
Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401
[TBL] [Abstract][Full Text] [Related]
5. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF
BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689
[TBL] [Abstract][Full Text] [Related]
6. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
7. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
Möllgård L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsäter K; Fioretos T; Andersson A; Paul C; Lehmann S
Cancer Chemother Pharmacol; 2008 Aug; 62(3):439-48. PubMed ID: 17960382
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
9. A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.
Breitenbuecher F; Markova B; Kasper S; Carius B; Stauder T; Böhmer FD; Masson K; Rönnstrand L; Huber C; Kindler T; Fischer T
Blood; 2009 Apr; 113(17):4063-73. PubMed ID: 19144992
[TBL] [Abstract][Full Text] [Related]
10. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
11. Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.
Huang A; Ju HQ; Liu K; Zhan G; Liu D; Wen S; Garcia-Manero G; Huang P; Hu Y
Cancer Lett; 2016 Jul; 377(2):149-57. PubMed ID: 27132990
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
[TBL] [Abstract][Full Text] [Related]
14. Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.
Patel RK; Weir MC; Shen K; Snyder D; Cooper VS; Smithgall TE
PLoS One; 2019; 14(12):e0225887. PubMed ID: 31790499
[TBL] [Abstract][Full Text] [Related]
15. Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.
Heidel F; Lipka DB; Mirea FK; Mahboobi S; Grundler R; Kancha RK; Duyster J; Naumann M; Huber C; Böhmer FD; Fischer T
Br J Haematol; 2009 Mar; 144(6):865-74. PubMed ID: 19183186
[TBL] [Abstract][Full Text] [Related]
16. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
[TBL] [Abstract][Full Text] [Related]
17. The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations.
Odgerel T; Kikuchi J; Wada T; Shimizu R; Futaki K; Kano Y; Furukawa Y
Oncogene; 2008 May; 27(22):3102-10. PubMed ID: 18071308
[TBL] [Abstract][Full Text] [Related]
18. MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
Zhang X; Li B; Yu J; Dahlström J; Tran AN; Björkholm M; Xu D
Ann Hematol; 2018 Jan; 97(1):63-72. PubMed ID: 29080039
[TBL] [Abstract][Full Text] [Related]
19. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
20. Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation.
Ortlepp C; Steudel C; Heiderich C; Koch S; Jacobi A; Ryser M; Brenner S; Bornhäuser M; Brors B; Hofmann WK; Ehninger G; Thiede C
Exp Hematol; 2013 May; 41(5):444-461.e4. PubMed ID: 23377000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
